HR Execs on the Move

RxAdvance

www.rxadvance.com

 
RxAdvance, a national full service PBM, leverages the disruptive Collaborative PBM Cloud™ to manage standard and specialty drug benefits with unmatched regulatory compliance and transparency. In addition, RxAdvance is willing to share global pharmacy risk, avoidable drug-impacted medical risk, and bundled episode specialty pharmacy risk, standing shoulder-to-shoulder with plan sponsors as a true accountable partner. This risk model has never been offered by any other PBM.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.rxadvance.com
  • 2 Park Central Drive
    Southborough, MA USA 01772
  • Phone: 508.804.6900

Executives

Name Title Contact Details

Similar Companies

Eisai

Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Medical Components

Dialysis and Vascular Access Products

ILC Dover

At SI Group, we create smart chemistry that solves global challenges and makes great things possible. We create smart chemistry that solves global challenges and makes great things possible. SI Group is a performance additives and intermediates business. We offer a broad array of products that feed into diverse applications including pharmaceuticals; plastics; oil and gas; and tires, among many others. We create solutions that provide formulators and manufacturers with the ability to increase efficacy, efficiency, productivity, and purity in countless industrial and consumer goods. Our company unites us. So do our values and the approach that we bring into the workplace each day.

QRxPharma Limited

QRxPharma Limited is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XORTX

XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.